Form 4: Kiniksa COO Boosts Equity Holdings Amid Planned Sales

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, increased direct share ownership and received new equity grants, while executing pre-planned sales.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (KNSA), engaged in multiple equity transactions between September 1, 2025, and September 3, 2025.
• Transactions included the acquisition of 8,209 Class A Ordinary Shares through the vesting and exercise of Restricted Share Units (RSUs) and 15,091 Class A Ordinary Shares through the exercise of stock options.
• A total of 3,972 Class A Ordinary Shares were disposed of to cover tax withholding obligations at prices of $33.49 and $34.28.
• An additional 15,091 Class A Ordinary Shares were sold at a weighted average price of $35.50, as part of a pre-arranged 10b5-1 trading plan established on April 29, 2024.
• Mr. Tessari was granted 9,828 new Restricted Share Units (RSUs) and 39,364 new Share Options on September 1, 2025.
• Following these transactions, Mr. Tessari's direct beneficial ownership of Class A Ordinary Shares increased from an implied 40,215 shares to 44,452 shares, alongside new grants of 9,828 RSUs and 39,364 Share Options.

Sentiment

Score: 7

Explanation: The sentiment is positive. The Chief Operating Officer increased their direct share ownership and received substantial new equity grants (RSUs and options), indicating continued alignment with shareholder interests. While some shares were sold, these were either for tax purposes or part of a pre-arranged 10b5-1 plan, mitigating any negative signal.

Positives

• The Chief Operating Officer's direct beneficial ownership of Class A Ordinary Shares increased by 4,237 shares following the reported transactions.
• Significant new grants of 9,828 Restricted Share Units and 39,364 Share Options were awarded, aligning management's interests with long-term shareholder value.
• Option exercises were executed at significantly lower prices ($15.50 and $15.52) compared to the sale price ($35.50), indicating profitable transactions for the officer.
• The sales of shares were either for tax withholding or conducted under a pre-arranged 10b5-1 plan, which suggests a structured approach to managing equity rather than a reactive disposition based on new information.

Negatives

• A total of 15,091 Class A Ordinary Shares were sold under a 10b5-1 plan, representing a reduction in the officer's direct equity exposure, even if pre-planned.

Future Outlook

The filing indicates future vesting events for the newly granted 9,828 Restricted Share Units, which will vest 25% on each yearly anniversary of the September 1, 2025 grant date. Additionally, the 39,364 new Share Options will vest 25% on the first anniversary of the September 1, 2025 vesting commencement date, followed by 36 equal monthly installments.

Industry Context

NA

Related Party Transactions

• The reported transactions involve an officer of Kiniksa Pharmaceuticals International, plc, engaging in equity dealings with the company's securities, which are inherently related-party transactions.

Stakeholder Impact

• Shareholders may view the net increase in the COO's direct share ownership and the new equity grants as a positive signal of management's continued commitment and alignment with long-term company performance.
• The pre-planned nature of the sales under a 10b5-1 plan helps to mitigate concerns that the sales are based on new, negative insider information.

Next Steps

• Continued vesting of 9,828 Restricted Share Units, with 25% vesting annually from September 1, 2025.
• Continued vesting of 39,364 Share Options, with 25% vesting on September 1, 2026, and the remainder in 36 equal monthly installments thereafter.

Key Dates

Recommendation

The filing details routine insider transactions, including option exercises and sales under a pre-arranged 10b5-1 plan, alongside new equity grants. The net effect on direct share ownership is an increase, and the new grants further align management's interests with shareholders. These activities do not suggest a fundamental change in the company's outlook or the officer's long-term commitment, thus warranting a 'hold' rather than a 'buy' or 'sell' based solely on this report.

Keywords

Kiniksa Pharmaceuticals, KNSA, SEC Form 4, Insider Trading, Stock Options, Restricted Share Units, 10b5-1 Plan, Eben Tessari, Chief Operating Officer, Equity Transactions